Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth KnowingZacks Investment Research · 5 days ago
Recursion Pharmaceuticals (NASDAQ:RXRX) Given Buy Rating at Needham & Company LLCDefense World · Oct 19, 2026
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their CollaborationGlobeNewsWire · Oct 15, 2026
Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common StockGlobeNewsWire · Oct 15, 2026
Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership MilestoneGlobeNewsWire · Oct 15, 2026
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to NoteZacks Investment Research · Oct 12, 2026Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$0.24 | -$0.25 | Miss |
| May 6, 2026 | -$0.30 | -$0.22 | Beat |
| Feb 25, 2026 | -$0.28 | -$0.21 | Beat |
| Nov 5, 2025 | -$0.38 | -$0.36 | Beat |
| Aug 5, 2025 | -$0.35 | -$0.41 | Miss |
| May 5, 2025 | -$0.44 | -$0.50 | Miss |